Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00177 ...
Drug Name Valsartan
Molecular Weight 435.5188
Molecular Formula C24H29N5O3
CAS Number 137862-53-4
SMILES CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
External Links
DRUGBANK DB00177
PubChem Compound 60846
PDR 24321
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 1.499 - 1.499 - http://www.japsonline.com/admin/php/uploads/54_pdf.pdf
Boiling Point 85.5 ℃ 83-88 ℃ https://www.trc-canada.com/product-detail/?V095750
Melting Point 116.5 ℃ 116-117 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB6182539.aspx
pKa 4.73 - 4.73 - http://www.japsonline.com/admin/php/uploads/54_pdf.pdf

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 23.0 % 23±7 % PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 1600.0 ng/ml 1.6±0.6 mcg/ml Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 5.0 h 4-6 h Oral single dose; patients; DRUGBANK
T Max 2.0 h 2(1.5-3) h Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Metabolic 9.0 % 9 % Liver metabolism; Drug form; DRUGBANK
Clearance 2.0 L/h ~2 L/h Plasma clearance; DRUGBANK
Clearance 0.62 L/h 0.62 L/h Renal clearance; DRUGBANK
Clearance 0.0294 L/h/kg 0.49±0.09 ml/min/kg normal,healthy; adults; Male, men; Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Clearance 0.0294 L/h/kg 0.49 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 17.0 L 17.0 L Steady state volume of distribution; intravenous injection, IV; DRUGBANK
Volume of Distribution 0.23 L/kg 0.23±0.09 L/kg normal,healthy; adults; Male, men; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.22 L/kg 0.22 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 6.0 h ~6 h intravenous injection, IV; elimination half-life; DRUGBANK
Half-life 9.4 h 9.4±3.8 h normal,healthy; adults; Male, men; Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 9.5 h 9.5 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 2000.0 mg/kg ~>2000 mg/kg intragastric; DRUGBANK
Eliminate Route 83.0 % ~83 % Faeces excretion; Liquid; DRUGBANK
Eliminate Route 13.0 % ~13 % Urinary excretion; Liquid; DRUGBANK
Eliminate Route 29.0 % 29±5.8 % Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 95.0 % 95 % DRUGBANK
Protein Binding 95.0 % 95 % adults; Male, men; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 2.7 mg/kg/day 2.7 mg/kg/day PO, oral Valsartan valsartan PDR
Max dose for children 160.0 mg/day 160 mg/day PO, oral Valsartan valsartan PDR
Max dose for adolescents 320.0 mg/day 320 mg/day PO, oral Valsartan valsartan PDR
Max dose for adolescents 2.7 mg/kg/day 2.7 mg/kg/day PO, oral Valsartan valsartan PDR
Max dose for adolescents 160.0 mg/day 160 mg/day PO, oral Valsartan valsartan PDR
Max dose for adults 320.0 mg/day 320 mg/day PO, oral Valsartan valsartan PDR
Max dose for geriatric 320.0 mg/day 320 mg/day PO, oral Valsartan valsartan PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1